Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068488 | 0.85 | TSHR (0.58) | VCAM1ALDH1A1MEN1KMT2AKAT2B | |
| SCHEMBL4520586 | 0.83 | VCAM1 (0.53) | VCAM1ALDH1A1KDM4EPOLB | |
| SCHEMBL9513445 | 0.83 | VCAM1 (0.55) | VCAM1ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL10959235 | 0.82 | TSHR (0.55) | ALDH1A1MEN1KMT2AKAT2B | |
| SCHEMBL29707970 | 0.81 | VCAM1 (0.56) | VCAM1ALDH1A1KDM4EPOLB | |
| SCHEMBL671271 | 0.81 | VCAM1 (0.54) | VCAM1ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL18653119 | 0.81 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL27311122 | 0.81 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLB | |
| SCHEMBL627966 | 0.81 | VCAM1 (0.51) | VCAM1ALDH1A1KDM4EPOLB | |
| SCHEMBL213965 | 0.81 | VCAM1 (0.56) | VCAM1ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0259362-A1 | PREPARATION OF 3-DIMETHYLAMINO-7-METHYL-1,2,4-BENZOTRIAZINE-1-OXIDE AND AZAPROPAZONE | A.H. ROBINS COMPANY LIMITED (GB) | 1988-03-16 | — | — | EP | claimed |
| WO-1987004432-A1 | PREPARATION OF 3-DIMETHYLAMINO-7-METHYL-1,2,4-BENZOTRIAZINE-1-OXIDE AND AZAPROPAZONE | A.H. ROBINS COMPANY LIMITED (GB) | 1987-07-30 | — | — | WO | claimed |
| CN-110272452-A | Quinoline derivatives and preparation method thereof and purposes | 山东中农联合生物科技股份有限公司 | 2019-09-24 | — | — | CN | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-1682547-B1 | RSV POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2012-10-24 | — | — | EP | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | DCB-USA, LLC (US) | 2011-07-07 | — | — | US | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-0268849-B1 | Poly(aminoaromatic) compounds | DOW CHEMICAL CO (US) | 1993-10-20 | — | — | EP | disclosed |
| US-5079275-A | Polyamino compound is an amino endcapped polyether, polyester, polycarbonate, resole, hydroxybutadiene | THE DOW CHEMICAL COMPANY (US) | 1992-01-07 | — | — | US | disclosed |
| US-4847416-A | Capping of polyols with aromatic amines | THE DOW CHEMICAL COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0268849-A2 | Poly(aminoaromatic) compounds | THE DOW CHEMICAL COMPANY (US) | 1988-06-01 | — | — | EP | disclosed |
| EP-0259362-A1 | PREPARATION OF 3-DIMETHYLAMINO-7-METHYL-1,2,4-BENZOTRIAZINE-1-OXIDE AND AZAPROPAZONE | A.H. ROBINS COMPANY LIMITED (GB) | 1988-03-16 | — | — | EP | disclosed |
| US-4700011-A | Methods for the production and purification of di (nitrophenyl) ethers | AMOCO CORPORATION (US) | 1987-10-13 | — | — | US | disclosed |
| WO-1987004432-A1 | PREPARATION OF 3-DIMETHYLAMINO-7-METHYL-1,2,4-BENZOTRIAZINE-1-OXIDE AND AZAPROPAZONE | A.H. ROBINS COMPANY LIMITED (GB) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | VCAM1 547/4885ALDH1A1 451/4885KDM4E 3395/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | VCAM1 85/4885ALDH1A1 486/4885KDM4E 3617/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | VCAM1 1775/4885ALDH1A1 1001/4885KDM4E 115/4885 |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | CTSS, CTSV, CTSB | VCAM1 1830/4885ALDH1A1 2734/4885KDM4E 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.